FINCK BARBARA K 4
4 · Coherus BioSciences, Inc. · Filed Sep 12, 2018
Insider Transaction Report
Form 4
FINCK BARBARA K
Chief Medical Officer
Transactions
- Sale
Common Stock, $0.0001 par value
2018-09-10$18.58/sh−1,760$32,699→ 37,043 total - Exercise/Conversion
Stock Option (right to buy)
2018-09-10−1,760→ 82,941 totalExercise: $1.42Exp: 2023-11-21→ Common Stock (1,760 underlying) - Exercise/Conversion
Common Stock, $0.0001 par value
2018-09-10$1.42/sh+1,760$2,499→ 38,803 total
Footnotes (3)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.
- [F2]The transaction was executed in multiple trades in prices ranging from $18.20 to $19.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- [F3]The shares underlying this option are fully vested and exercisable as of the date hereof.